article thumbnail

ASRS conference reveals hopeful outcomes for gene therapy RGX-314 in retinal diseases

Pharmaceutical Technology

The spotlight was placed on many up-and-coming pharmacotherapies for retinal diseases, one of which was AbbVie’s/Regenxbio’s gene therapy RGX-314. RGX-314 stands out, however, by offering a unique feature unlike any other anti-VEGF treatment, as it is a gene therapy, thereby offered as a one-time treatment.

article thumbnail

Alyftrek: Vertex Expands Cystic Fibrosis Treatment with Triple-Action Combo

XTalks

The CFTR gene itself is complex, with over 2,000 known mutations. The diversity of CF treatments is expanding with investigational therapies such as Spirovants inhaled gene therapy SP-101 in a Phase I/II trial and Kither Biotechs inhaled peptide therapy KIT2014 in a Phase I trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ATMPS and Assurea team up to ensure audit readiness for cell and gene therapy innovators

BioPharma Reporter

ATMPS Ltd, a UK developer of blockchain-based cell orchestration platforms for advanced therapies is collaborating with US quality and compliance consultancy, Assurea LLC, to develop a fully complaint blockchain approach for end-to-end supply chain management of cell and gene therapies.

article thumbnail

Unlocking the Future of Personalized Medicine: Blood vs. Buccal Swab in Pharmacogenomics Testing

Worldwide Clinical Trials

Pharmacogenomics (PGx), the study of how genes affect a person’s response to drugs, has brought significant changes to the clinical trial industry. Patient Compliance One of the most important findings of the study was the difference in patient compliance between the two sample collection methods.

Medicine 182
article thumbnail

Mastering 21 CFR Part 11 Compliance: A Comprehensive Guide for Clinical Trials in the Digital Age

Cloudbyz

21 CFR Part 11 is a crucial component of regulatory compliance in clinical trials and, more broadly, any industry subject to the regulations of the U.S. This blog post will serve as a comprehensive guide to understanding and implementing 21 CFR Part 11 compliance in your clinical trials. Food and Drug Administration (FDA).

article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

The next wave of medicine is well on course to be cell and gene-based. For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Meanwhile, the pharma industry is undergoing somewhat of a transformation itself.

Drugs 295
article thumbnail

Tamibarotene Fails in Phase III Trial for a Subset of Higher-Risk MDS

XTalks

The trial was evaluating the drug in combination with the chemotherapy azacitidine for the treatment of newly diagnosed patients with higher-risk myelodysplastic syndrome (HR-MDS) who harbor overexpression of the RARA (retinoic acid receptor alpha) gene.

Trials 105